HCG Aastha Cancer Centre Achieves First CAR-T Cell Therapy Milestone for Refractory Lymphoma in Gujarat
核心洞察
HCG Aastha Cancer Centre (搜索) in Ahmedabad successfully completed its first CAR-T cell therapy (搜索) on a patient with primary refractory lymphoma (搜索), an aggressive blood cancer unresponsive to conventional treatment.
The procedure was led by Dr. Kaumil Patel and a multidisciplinary team trained in advanced cellular therapies, marking expanded access to personalized immunotherapy in Gujarat.
CAR-T therapy involves genetically modifying a patient's own T-cells to recognize and attack cancer cells, offering hope when chemotherapy and immunotherapy have failed.
HCG Aastha Cancer Centre (搜索) in Ahmedabad has successfully completed its first CAR-T cell therapy (搜索) procedure, marking a significant advancement in the availability of next-generation personalized immunotherapy for patients across Gujarat and neighboring regions. The landmark treatment was performed on a patient diagnosed with primary refractory lymphoma (搜索), an aggressive blood cancer that had failed to respond to conventional treatment approaches.
The CAR-T cell therapy (搜索) program at HCG Aastha Cancer Centre (搜索) is led by Dr. Kaumil Patel, Consultant in Hematology, Bone Marrow Transplantation (BMT), and CAR-T Cell Therapy Specialist, supported by a dedicated multidisciplinary team trained in advanced cellular therapies and the comprehensive management of complex hematological malignancies.
A New Frontier in Precision Immunotherapy
CAR-T cell therapy (搜索) represents one of the most advanced forms of personalized cancer immunotherapy available today. The treatment involves collecting a patient's own T-cells, genetically modifying them to recognize and attack cancer cells, and then reinfusing them into the patient. This highly specialized therapy has transformed treatment outcomes for patients with aggressive blood cancers that have failed conventional options such as chemotherapy and immunotherapy.
"The successful completion of our first CAR-T Cell Therapy (搜索) reflects the evolution of blood cancer treatment from conventional approaches to precision immunotherapy," said Dr. Kaumil Patel. "For patients with relapsed or refractory lymphoma, this therapy offers a meaningful opportunity when other treatment options have failed. More importantly, it demonstrates that highly specialized cellular therapies can now be delivered safely with international standards of care, enabling patients to access advanced treatment much closer to home."
Infrastructure and Multidisciplinary Expertise
The successful delivery of CAR-T cell therapy (搜索) requires sophisticated infrastructure, multidisciplinary expertise, advanced transfusion and cellular therapy support, dedicated intensive monitoring facilities, and specialized management of treatment-related complications. Only a limited number of centers in Gujarat currently possess the expertise, infrastructure, and clinical capabilities required to safely perform CAR-T cell therapy and manage its associated complexities.
Dr. Bharat Gadhavi, Regional Director for Gujarat and Jaipur at HCG, emphasized the institutional commitment behind this achievement: "Establishing a CAR-T Cell Therapy (搜索) programme requires far more than technology—it demands specialized expertise, integrated infrastructure, and coordinated multidisciplinary care. Successfully delivering this therapy reinforces our vision of bringing world-class cancer treatment within reach for patients across Gujarat and surrounding regions."
Patient Impact and Clinical Indications
The patient expressed gratitude for the care received, stating, "The journey has not been easy, but I never felt alone. From the very beginning, the doctors and hospital staff supported me with compassion, answered every question patiently, and gave me the confidence to move forward."
CAR-T cell therapy (搜索) may be considered for carefully selected patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (搜索) (DLBCL), primary refractory aggressive B-cell lymphomas, high-grade B-cell lymphoma, selected cases of follicular lymphoma and mantle cell lymphoma, relapsed B-cell acute lymphoblastic leukemia (搜索) (ALL), and selected patients with multiple myeloma (搜索) after multiple prior lines of therapy.
Sudarshan Bhamare, Chief Operating Officer of HCG Aastha Cancer Centre (搜索), noted that the successful completion of the procedure reflects the center's commitment to providing comprehensive hematology, hemato-oncology, bone marrow transplantation, and advanced cellular therapy services at standards comparable to leading international cancer centers.
Growing Adoption Across Ahmedabad
The broader adoption of CAR-T cell therapy (搜索) in Ahmedabad is gaining momentum. According to hematologists in the city, it has been two years since the therapy was introduced, and hospitals are inching closer to the 50-procedure mark, with several private hospitals now offering the treatment. Dr. Velu Nair, chief consultant of hemato-oncology at Apollo Hospital, reported encouraging results from two procedures performed at his center, with more cases in the pipeline. Dr. Sandip Shah, a hemato-oncologist with HOC Vedanta, also confirmed several successful procedures, while emphasizing that the therapy is not suitable for everyone and requires careful individual case assessment.
By expanding access to advanced cellular therapies such as CAR-T cell therapy (搜索), HCG Aastha Cancer Centre (搜索) continues to strengthen its commitment to delivering innovative, evidence-based, and patient-centric cancer care while making transformative treatments accessible closer to home.